Full text is available at the source.
Abstract
Comparisons among once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are limited.
- The lack of comparisons may hinder optimal clinical treatment choices.
- Current evidence does not provide a clear hierarchy of effectiveness among these medications.
- A need for more comprehensive studies exists to evaluate the comparative efficacy of once-weekly GLP-1RAs.
Simplified